IOVA Earnings Prediction
The chart below shows how IOVA performed 10 days before and after its earnings report, based on data from the past quarters. Typically, IOVA sees a -4.28% change in stock price 10 days leading up to the earnings, and a -0.38% change 10 days following the report. On the earnings day itself, the stock moves by +0.99%. This data can give you a slight idea of what to expect for the next quarter's release.
IOVA Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
58.55M
12385.07%
88.24%
Gross Margin
37.22%
104.51%
469.11%
Operating Margin
-152.11%
-99.40%
-53.57%
Net Margin
-142.67%
-99.41%
-78.39%
EPS
-0.28
-39.13%
-17.65%
No Data Available
IOVA Earnings Analysis
Iovance Biotherapeutics, Inc. Common Stock Corporation (IOVA.O) Earnings Conference Call
Positive
Q3 Revenue Surpasses Guidance: Total product revenue for the third quarter was $58.6 million, surpassing the top end of our third quarter total product revenue guidance of $53 million to $55 million.
Total Product Revenue Breakdown: Total product revenue for the first nine months of 2024 was $90.4 million, including $54.9 million for Amtagvi and $35.5 million for Proleukin.
Year-over-Year Growth Expectations: We expect a significant increase in year-over-year growth as ATCs broaden utilization and new ATCs as well as community referral networks contribute to additional demand.
Revenue Guidance Reaffirmation: We are reaffirming our fully year 2024 total product revenue guidance of $160 million to $165 million and reiterating our fully year 2025 guidance of $450 million to $475 million in total product revenue.
Manufacturing Capacity Expansion: Our manufacturing capacity continues its steady ramp up month over month to support the growing Amtagvi commercial demand.
Negative
Quarterly Net Loss Comparison: Net loss for the third quarter of 2024 was $83.5 million, or $0.28 per share, compared to a net loss of $113.8 million, or $0.46 per share for the third quarter ended September 30, 2023.
Net Loss Comparison: Net loss for the first nine months of 2024 was $293.6 million, or $1.03 per share, compared to a net loss of $327.7 million, or $1.44 per share, for the nine month period ended September 30, 2023.
R&D Expense Decrease: Research and development expenses were $68.2 million for the third quarter of 2024, a decrease of $19.3 million compared to $87.5 million for the same period ended September 30, 2023.
SG&A Expense Increase: Selling, general and administrative expenses were $39.6 million for the third quarter of 2024, an increase of $12.6 million compared to $27 million for the same period ended September 30, 2023.
Q3 2024 Product Revenue: Total product revenue for the third quarter of 2024 was $58.6 million, including $42.1 million for Amtagvi and $16.5 million for Proleukin.
IOVA FAQs
How does IOVA typically perform around its earnings report dates?
Is Iovance Biotherapeutics, Inc. (IOVA) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
IOVA Earning Call Sentiment
Iovance Biotherapeutics, Inc. (IOVA) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
IOVA.O
3.03%Positive
The earnings call reflects strong financial performance with significant revenue growth and improved margins, despite continued net losses. The optimistic guidance for 2024 and 2025, coupled with a solid cash position, suggests a positive outlook. The Q&A reveals steady demand and operational improvements, although some uncertainties remain. Overall, the market cap indicates moderate sensitivity, leading to a 'Positive' prediction of 2% to 8% stock price increase over the next two weeks.
